Prevention strategies for gastric cancer: A global perspective

Clinical Endoscopy

Volumn 47, Issue 6, 2014, Pages 478-489

  Park, Jin Young ^a   von Karsa, Lawrence ^a   Herrero, Rolando ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Mass screening; Prevention; Stomach neoplasms

Indexed keywords

EID: 84912117511     PISSN: 22342400     EISSN: 22342443     Source Type: Journal    
DOI: 10.5946/ce.2014.47.6.478     Document Type: Article

References (99)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer; 2013 [cited 2014 Apr 25]. Available from: http://globocan.iarc.fr.
2. Carneiro F. Stomach cancer. In: Steward, B W, Wild, C P, eds. World Cancer Report 2014. Lyon: International Agency for Research on Cancer; 2014. p. 383-391.
3. Ferlay J, Bray F, Steliarova-Foucher E, Forman D. Cancer incidence in fve continents, CI5plus: IARC CancerBase No. 9 [Internet]. Lyon: International Agency for Research on Cancer; 2014 [cited 2014 Apr 25]. Available from: http://ci5.iarc.fr.
4. Forman D, Sierra MS. Introduction: the current and projected global burden of gastric cancer. In: IARC Helicobacter pylori Working Group, ed. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer [Internet]. Lyon: International Agency for Research on Cancer (IARC Working Group Reports, No. 8); 2014 [cited 2014 Apr 25]. p. 5-15. Available from: http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php.
5. Jung K W, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat 2014;46:109-123.
6. Choi IJ, Park JY, Herrero R. Efect of Helicobacter pylori eradication on gastric cancer prevention in the Republic of Korea: a randomized controlled clinical trial. In: IARC Helicobacter pylori Working Group, ed. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer [Internet]. Lyon: International Agency for Research on Cancer (IARC Working Group Reports, No. 8); 2014 [cited 2014 Apr 25]. p. 154-160. Available from: http://www.iarc.fr/en/publications/pdfs-on-line/wrk/wrk8/index.php.
7. National Cancer Center. Cancer Facts & Figures 2013 in the Republic of Korea. Goyang: President of National Cancer Center, Minister for Health and Welfare; 2013. 8p.
8. Lauwers GY, Carneiro F, Graham DY, et al. Gastric carcinoma. In: Bos-man FT, Carneiro F, Hruban RH, Teise ND, eds. WHO Classifcation of Tumours of the Digestive System. Lyon: International Agency for Research on Cancer; 2010. p. 48-58.
9. Correa P. A human model of gastric carcinogenesis. Cancer Res 1988; 48:3554-3560.
10. Lauren P. Te two histological main types of gastric carcinoma: difuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classifcation. Acta Pathol Microbiol Scand 1965;64:31-49.
11. Lauwers GY, Shimizu M, Correa P, et al. Evaluation of gastric biopsies for neoplasia: diferences between Japanese and Western pathologists. Am J Surg Pathol 1999;23:511-518.
12. Dixon M F. Gastrointestinal epithelial neoplasia: Vienna revisited. Gut 2002;51:130-131.
13. Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precan-cerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012;44:74-94.
14. Yada T, Yokoi C, Uemura N. Te current state of diagnosis and treatment for early gastric cancer. Diagn Ter Endosc 2013;2013:241320.
15. Schlemper RJ, Riddell RH, Kato Y, et al. Te Vienna classifcation of gastrointestinal epithelial neoplasia. Gut 2000;47:251-255.
16. Participants in the Paris Workshop. Te Paris endoscopic classifcation of superfcial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc 2003;58(6 Suppl): S3-S43.
17. Hu B, El Hajj N, Sittler S, Lammert N, Barnes R, Meloni-Ehrig A. Gastric cancer: classifcation, histology and application of molecular pathology. J Gastrointest Oncol 2012;3:251-261.
18. Yoshikawa K, Maruyama K. Characteristics of gastric cancer invading to the proper muscle layer: with special reference to mortality and cause of death. Jpn J Clin Oncol 1985;15:499-503.
19. Everett SM, Axon AT. Early gastric cancer in Europe. Gut 1997;41:142-150.
20. Yokota T, Kunii Y, Teshima S, et al. Signifcant prognostic factors in patients with early gastric cancer. Int Surg 2000;85:286-290.
21. Kim DY, Joo JK, Ryu SY, Park YK, Kim YJ, Kim SK. Clinicopathologic characteristics of gastric carcinoma in elderly patients: a comparison with young patients. World J Gastroenterol 2005;11:22-26.
22. Strong VE, Song K Y, Park CH, et al. Comparison of disease-specifc survival in the United States and Korea afer resection for early-stage node-negative gastric carcinoma. J Surg Oncol 2013;107:634-640.
23. Dixon M F, Genta RM, Yardley JH, Correa P. Classifcation and grading of gastritis. Te updated Sydney System. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 1996; 20:1161-1181.
24. Rugge M, Meggio A, Pennelli G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut 2007;56:631-636.
25. Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis 2008;40:650-658.
26. Capelle LG, de Vries AC, Haringsma J, et al. Te staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc 2010;71:1150-1158.
27. Carneiro F, Huntsman DG, Smyrk TC, et al. Model of the early development of difuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. J Pathol 2004;203:681-687.
28. Carneiro F, Oliveira C, Suriano G, Seruca R. Molecular pathology of familial gastric cancer, with an emphasis on hereditary difuse gastric cancer. J Clin Pathol 2008;61:25-30.
29. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev 2014;23:700-713.
30. Capelle LG, Van Grieken NC, Lingsma HF, et al. Risk and epidemio-logical time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology 2010;138:487-492.
31. Masciari S, Dewanwala A, Stofel EM, et al. Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med 2011;13:651-657.
32. Song SH, Kim KW, Kim WH, et al. Gastrointestinal cancers in a peutz-jeghers syndrome family: a case report. Clin Endosc 2013;46:572-575.
33. Takahashi M, Sakayori M, Takahashi S, et al. A novel germline mutation of the LKB1 gene in a patient with Peutz-Jeghers syndrome with early-onset gastric cancer. J Gastroenterol 2004;39:1210-1214.
34. El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404:398-402.
35. Kamangar F, Cheng C, Abnet CC, Rabkin CS. Interleukin-1B polymorphisms and gastric cancer risk: a meta-analysis. Cancer Epidemiol Bio-markers Prev 2006;15:1920-1928.
36. González CA, Megraud F, Buissonniere A, et al. Helicobacter pylori infection assessed by ELISA and by immunoblot and noncardia gastric cancer risk in a prospective study: the Eurgast-EPIC project. Ann Oncol 2012;23:1320-1324.
37. Lochhead P, El-Omar EM. Helicobacter pylori infection and gastric cancer. Best Pract Res Clin Gastroenterol 2007;21:281-297.
38. IARC Working Group. Helicobacter pylori. In: IARC Working Group, ed. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 100B. Biological Agents. Lyon: International Agency for Research on Cancer; 2012. p. 385-436.
39. Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to pylori. Int J Cancer 2015;136: 487-490.
40. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-1186.
41. Porras C, Nodora J, Sexton R, et al. Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701). Cancer Causes Control 2013;24:209-215.
42. Oona M, Utt M, Nilsson I, Uibo O, Vorobjova T, Maaroos HI. Helicobacter pylori infection in children in Estonia: decreasing seroprevalence during the 11-year period of profound socioeconomic changes. Helico-bacter 2004;9:233-241.
43. Yim JY, Kim N, Choi SH, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 2007;12:333-340.
44. Leja M, Cine E, Rudzite D, et al. Prevalence of Helicobacter pylori infection and atrophic gastritis in Latvia. Eur J Gastroenterol Hepatol 2012;24:1410-1417.
45. Peek RM Jr, Crabtree JE. Helicobacter infection and gastric neoplasia. J Pathol 2006;208:233-248.
46. Peek RM Jr, Vaezi MF, Falk G W, et al. Role of Helicobacter pylori cagA(+) strains and specifc host immune responses on the development of premalignant and malignant lesions in the gastric cardia. Int J Cancer 1999;82:520-524.
47. Buti L, Spooner E, Van der Veen AG, Rappuoli R, Covacci A, Ploegh HL. Helicobacter pylori cytotoxin-associated gene A (CagA) subverts the apoptosis-stimulating protein of p53 (ASPP2) tumor suppressor pathway of the host. Proc Natl Acad Sci U S A 2011;108:9238-9243.
48. Gebert B, Fischer W, Weiss E, Hofmann R, Haas R. Helicobacter pylori vacuolating cytotoxin inhibits T lymphocyte activation. Science 2003; 301:1099-1102.
49. IARC Working Group. Epstein-Barr virus. In: IARC Working Group, ed. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol. 70. Epstein-Barr Virus and Kaposi’s Sarcoma Herpesvirus/Human Herpesvirus 8. Lyon: International Agency for Research on Cancer; 1997. p. 47-373.
50. Camargo MC, Murphy G, Koriyama C, et al. Determinants of Epstein-Barr virus-positive gastric cancer: an international pooled analysis. Br J Cancer 2011;105:38-43.
51. Camargo MC, Kim WH, Chiaravalli AM, et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut 2014;63:236-243.
52. World Cancer Research Fund; American Institute for Cancer Research. Stomach. In: World Cancer Research Fund; American Institute for Cancer Research, eds. Food, Nutrition, Physical Activity, and the Prevention of Cancer: a Global Perspective. Washington DC: WCRF/AICR; 2007. p. 265-270.
53. Cohen AJ, Roe FJ. Evaluation of the aetiological role of dietary salt exposure in gastric and other cancers in humans. Food Chem Toxicol 1997;35:271-293.
54. Furihata C, Ohta H, Katsuyama T. Cause and efect between concentration-dependent tissue damage and temporary cell proliferation in rat stomach mucosa by NaCl, a stomach tumor promoter. Carcinogenesis 1996;17:401-406.
55. Tsugane S, Sasazuki S, Kobayashi M, Sasaki S. Salt and salted food intake and subsequent risk of gastric cancer among middle-aged Japanese men and women. Br J Cancer 2004;90:128-134.
56. Fox JG, Dangler CA, Taylor NS, King A, Koh TJ, Wang TC. High-salt diet induces gastric epithelial hyperplasia and parietal cell loss, and enhances Helicobacter pylori colonization in C57BL/6 mice. Cancer Res 1999;59:4823-4828.
57. Gaddy JA, Radin JN, Loh JT, et al. High dietary salt intake exacerbates Helicobacter pylori-induced gastric carcinogenesis. Infect Immun 2013;81:2258-2267.
58. Kato S, Tsukamoto T, Mizoshita T, et al. High salt diets dose-depend-ently promote gastric chemical carcinogenesis in Helicobacter pylori-infected Mongolian gerbils associated with a shif in mucin production from glandular to surface mucous cells. Int J Cancer 2006;119:1558-1566.
59. Toyoda T, Tsukamoto T, Hirano N, et al. Synergistic upregulation of in-ducible nitric oxide synthase and cyclooxygenase-2 in gastric mucosa of Mongolian gerbils by a high-salt diet and Helicobacter pylori infection. Histol Histopathol 2008;23:593-599.
60. Loh JT, Torres VJ, Cover TL. Regulation of Helicobacter pylori cagA expression in response to salt. Cancer Res 2007;67:4709-4715.
61. Loh YH, Jakszyn P, Luben RN, Mulligan AA, Mitrou PN, Khaw KT. N-Nitroso compounds and cancer incidence: the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk Study. Am J Clin Nutr 2011;93:1053-1061.
62. Jakszyn P, Bingham S, Pera G, et al. Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EUR-GAST) study. Carcinogenesis 2006;27:1497-1501.
63. Rokkas T, Liatsos C, Petridou E, et al. Relationship of Helicobacter pylori CagA(+) status to gastric juice vitamin C levels. Eur J Clin Invest 1999;29:56-62.
64. Zhang Z W, Patchett SE, Perrett D, Katelaris PH, Domizio P, Farthing MJ. Te relation between gastric vitamin C concentrations, mucosal histology, and CagA seropositivity in the human stomach. Gut 1998; 43:322-326.
65. Graham DY, Shiotani A. Te time to eradicate gastric cancer is now. Gut 2005;54:735-738.
66. Park JY, Forman D, Greenberg ER, Herrero R. Helicobacter pylori eradication in the prevention of gastric cancer: are more trials needed? Curr Oncol Rep 2013;15:517-525.
67. Greenberg ER, Park JY. Efectiveness of Helicobacter pylori eradication. In: IARC Helicobacter pylori Working Group, ed. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer [Internet]. Lyon: International Agency for Research on Cancer (IARC Working Group Reports, No. 8); 2014 [cited 2014 Apr 25]. p. 64-71. Available from: http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index. php.
68. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 2014;348:g3174.
69. Ma JL, Zhang L, Brown LM, et al. Fifeen-year efects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 2012;104:488-492.
70. Choi J, Kim SG, Yoon H, et al. Eradication of Helicobacter pylori afer endoscopic resection of gastric tumors does not reduce incidence of metachronous gastric carcinoma. Clin Gastroenterol Hepatol 2014;12: 793-800.
71. Fukase K, Kato M, Kikuchi S, et al. Efect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endo-scopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392-397.
72. Herrero R, Parsonnet J, Greenberg ER. Prevention of gastric cancer. JAMA 2014;312:1197-1198.
73. IARC Helicobacter pylori Working Group. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer [Internet]. Lyon: International Agency for Research on Cancer (IARC Working Group Reports, No. 8); 2014 [cited 2014 Apr 25]. Available from: http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php.
74. Park JY, Greenberg ER, Parsonnet J, Wild CP, Forman D, Herrero R. Summary of IARC Working Group Meeting on Helicobacter pylori eradication as a strategy for preventing gastric cance. In: IARC Helico-bacter pylori Working Group, ed. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer [Internet]. Lyon: International Agency for Research on Cancer (IARC Working Group Reports, No. 8); 2014 [cited 2014 Apr 25]. p. 1-4. Available from: http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php.
75. Leung WK, Wu MS, Kakugawa Y, et al. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol 2008;9:279-287.
76. Tsubono Y, Hisamichi S. Screening for gastric cancer in Japan. Gastric Cancer 2000;3:9-18.
77. Choi KS, Jun JK, Lee H Y, et al. Performance of gastric cancer screening by endoscopy testing through the National Cancer Screening Program of Korea. Cancer Sci 2011;102:1559-1564.
78. Hamashima C, Shibuya D, Yamazaki H, et al. Te Japanese guidelines for gastric cancer screening. Jpn J Clin Oncol 2008;38:259-267.
79. Areia M, Carvalho R, Cadime AT, Rocha Goncalves F, Dinis-Ribeiro M. Screening for gastric cancer and surveillance of premalignant lesions: a systematic review of cost-efectiveness studies. Helicobacter 2013;18:325-337.
80. Choi KS, Jun JK, Park EC, et al. Performance of diferent gastric cancer screening methods in Korea: a population-based study. PLoS One 2012; 7:e50041.
81. Matsumoto S, Ishikawa S, Yoshida Y. Reduction of gastric cancer mortality by endoscopic and radiographic screening in an isolated island: A retrospective cohort study. Aust J Rural Health 2013;21:319-324.
82. Riecken B, Pfeifer R, Ma JL, et al. No impact of repeated endoscopic screens on gastric cancer mortality in a prospectively followed Chinese population at high risk. Prev Med 2002;34:22-28.
83. Hamashima C, Ogoshi K, Okamoto M, Shabana M, Kishimoto T, Fu-kao A. A community-based, case-control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan. PLoS One 2013;8:e79088.
84. Lee HY, Park EC, Jun JK, Choi KS, Hahm MI. Comparing upper gastrointestinal X-ray and endoscopy for gastric cancer diagnosis in Korea. World J Gastroenterol 2010;16:245-250.
85. Tashiro A, Sano M, Kinameri K, Fujita K, Takeuchi Y. Comparing mass screening techniques for gastric cancer in Japan. World J Gastroenterol 2006;12:4873-4874.
86. Nam SY, Choi IJ, Park K W, et al. Efect of repeated endoscopic screening on the incidence and treatment of gastric cancer in health screenees. Eur J Gastroenterol Hepatol 2009;21:855-860.
87. Agreus L, Kuipers EJ, Kupcinskas L, et al. Rationale in diagnosis and screening of atrophic gastritis with stomach-specifc plasma biomark-ers. Scand J Gastroenterol 2012;47:136-147.
88. Miki K. Gastric cancer screening using the serum pepsinogen test method. Gastric Cancer 2006;9:245-253.
89. Mizuno S, Miki I, Ishida T, et al. Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis. Dig Dis Sci 2010;55:3132-3137.
90. Ohata H, Kitauchi S, Yoshimura N, et al. Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138-143.
91. Zhang X, Xue L, Xing L, et al. Low serum pepsinogen I and pepsinogen I/II ratio and Helicobacter pylori infection are associated with increased risk of gastric cancer: 14-year follow up result in a rural Chinese community. Int J Cancer 2012;130:1614-1619.
92. Torres J. Te role of biomarkers of gastric cancer risk to target interventions. In: IARC Helicobacter pylori Working Group, ed. Helicobacter pylori Eradication as a Strategy for Preventing Gastric Cancer [Internet]. Lyon: International Agency for Research on Cancer (IARC Working Group Reports, No. 8); 2014 [cited 2014 Apr 25]. p. 122-135. Available from: http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php.
93. Sipponen P, Ranta P, Helske T, et al. Serum levels of amidated gas-trin-17 and pepsinogen I in atrophic gastritis: an observational case-control study. Scand J Gastroenterol 2002;37:785-791.
94. Väänänen H, Vauhkonen M, Helske T, et al. Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: a multicentre study. Eur J Gastroenterol Hepatol 2003;15:885-891.
95. Leja M, Kupcinskas L, Funka K, et al. Value of gastrin-17 in detecting antral atrophy. Adv Med Sci 2011;56:145-150.
96. Tu H, Sun L, Dong X, et al. Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: a longitudinal study. Int J Cancer 2014;136:425-434.
97. von Karsa L, Qiao YL, Ramadas K, Keita N, Arrossi S, Dean PB. Screening: implementation. In: Stewart BW, Wild CP, eds. World Cancer Report 2014. Lyon: International Agency for Research on Cancer; 2014. p. 330-336.
98. Karsa LV, Lignini TA, Patnick J, Lambert R, Sauvaget C. Te dimensions of the CRC problem. Best Pract Res Clin Gastroenterol 2010;24: 381-396.
99. von Karsa L, Dean PB, Arrossi S, Sankaranarayanan R. Screening: principles. In: Stewart B W, Wild C P, eds. World Cancer Report 2014. Lyon: International Agency for Research on Cancer; 2014. p. 322-329.